The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Gentamicin‐induced readthrough of stop codons in duchenne muscular dystrophy
Abstract
Objective: The objective of this study was to establish the feasibility of long‐term gentamicin dosing to achieve stop codon readthrough and produce full‐length dystrophin. Mutation suppression of stop codons, successfully achieved in the mdx mouse using gentamicin, represents an important evolving treatment strategy in Duchenne muscular dystrophy (DMD). Methods: Two DMD cohorts received 14‐day gentamicin (7.5mg/kg/day): Cohort 1 (n = 10) stop codon patients and Cohort 2 (n = 8) frameshift controls. Two additional stop codon DMD cohorts were gentamicin treated (7.5mg/kg) for 6 months: Cohort 3 (n = 12) dosed weekly and Cohort 4 (n = 4) dosed twice weekly. Pre‐ and post‐treatment biopsies were assessed for dystrophin levels, as were clinical outcomes. Results: In the 14‐day study, serum creatine kinase (CK) dropped by 50%, which was not seen in frameshift DMD controls. After 6 months of gentamicin, dystrophin levels significantly increased ( p = 0.027); the highest levels reached 13 to 15% of normal (1 in Cohort 3, and 2 in Cohort 4), accompanied by reduced serum CK favoring drug‐induced readthrough of stop codons. This was supported by stabilization of strength and a slight increase in forced vital capacity. Pretreatment stable transcripts predicted an increase of dystrophin after gentamicin. Readthrough efficiency was not affected by the stop codon or its surrounding fourth nucleotide. In 1 subject, antigen‐specific interferon‐γ enzyme‐linked immunospot assay detected an immunogenic dystrophin epitope. Interpretation: The results support efforts to achieve drug‐induced mutation suppression of stop codons. The immunogenic epitope resulting from readthrough emphasizes the importance of monitoring T‐cell immunity during clinical studies that suppress stop codons. Similar principles apply to other molecular strategies, including exon skipping and gene therapy. ANN NEUROL 2010;67:771–780
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
Ramsey, B. W., Pepe, M. S., Quan, J. M., Otto, K. L., Montgomery, A. B., Williams-Warren, J., Vasiljev-K, M., Borowitz, D., Bowman, C. M., Marshall, B. C., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400104 · Cited by 1,300
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice
Barton-Davis, E. R., Cordier, L., Shoturma, D. I., Leland, S. E., & Sweeney, H. L. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7866 · Cited by 585
Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy
Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Fenichel, G. M., Miller, J. P., King, W., Signore, L., Pandya, S., Florence, J., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906153202405 · Cited by 520
Self-citationAminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations
Howard, M., Frizzell, R. A., & Bedwell, D. M. (1996) · Nature Medicine · doi:10.1038/nm0496-467 · Cited by 493
STREPTOMYCIN, SUPPRESSION, AND THE CODE
Davies, J., Gilbert, W., & Gorini, L. (1964) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.51.5.883 · Cited by 474
Aminoglycoside-Induced Ototoxicity
Selimoglu, E. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207779313731 · Cited by 446
Brooke, M. H., Fenichel, G. M., Griggs, R. C., Mendell, J. R., Moxley, R., Miller, J. P., & Province, M. A. (1983) · Muscle & Nerve · doi:10.1002/mus.880060204 · Cited by 353
Self-citationSuppression of a CFTR premature stop mutation in a bronchial epithelial cell line
Bedwell, D. M., Kaenjak, A., Benos, D. J., Bebok, Z., Bubien, J. K., Hong, J., Tousson, A., Clancy, J. P., & Sorscher, E. J. (1997) · Nature Medicine · doi:10.1038/nm1197-1280 · Cited by 343
Bonetti, B., Fu, L., Moon, J., & Bedwell, D. M. (1995) · Journal of Molecular Biology · doi:10.1006/jmbi.1995.0438 · Cited by 307
Cited by
Duan, D., Goemans, N., Takeda, S., Mercuri, E., & Aartsma-Rus, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00248-3 · Cited by 1,312
Evidence-based path to newborn screening for Duchenne muscular dystrophy
Mendell, J. R., Shilling, C., Leslie, N. D., Flanigan, K. M., al‐Dahhak, R., Gastier‐Foster, J., Kneile, K., Dunn, D. M., Duval, B., Aoyagi, A., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23528 · Cited by 813
Self-citationRare-disease genetics in the era of next-generation sequencing: discovery to translation
Boycott, K. M., Vanstone, M. R., Bulman, D. E., & MacKenzie, A. E. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3555 · Cited by 763
Ataluren treatment of patients with nonsense mutation dystrophinopathy
Bushby, K., Finkel, R., Wong, B., Barohn, R., Campbell, C., Comi, G. P., Connolly, A. M., Day, J. W., Flanigan, K. M., Goemans, N., et al. (2014) · Muscle & Nerve · doi:10.1002/mus.24332 · Cited by 428
Self-citationTherapeutic developments for Duchenne muscular dystrophy
Verhaart, I. E. C., & Aartsma-Rus, A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0203-3 · Cited by 377
Cisplatin and Aminoglycoside Antibiotics: Hearing Loss and Its Prevention
Schacht, J., Talaska, A. E., & Rybak, L. P. (2012) · The Anatomical Record · doi:10.1002/ar.22578 · Cited by 348
Therapeutics Based on Stop Codon Readthrough
Keeling, K. M., Xue, X., Gunn, G., & Bedwell, D. M. (2014) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091212-153527 · Cited by 306
The Pathogenesis and Therapy of Muscular Dystrophies
Guiraud, S., Aartsma-Rus, A., Vieira, N. M., Davies, K. E., van Ommen, G.-J. B., & Kunkel, L. M. (2015) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090314-025003 · Cited by 302
New developments in aminoglycoside therapy and ototoxicity
Xie, J., Talaska, A. E., & Schacht, J. (2011) · Hearing Research · doi:10.1016/j.heares.2011.05.008 · Cited by 287
Egawa, G., & Kabashima, K. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.06.002 · Cited by 265
Adachi, T., El-Hattab, A. W., Jain, R., Nogales Crespo, K. A., Quirland Lazo, C. I., Scarpa, M., Summar, M., & Wattanasirichaigoon, D. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20064732 · Cited by 168
“demonstrated its effectiveness and long-term safety in treating this RD [61].”
BackgroundFlanigan, K. M., Campbell, K., Viollet, L., Wang, W., Gomez, A. M., Walker, C. M., & Mendell, J. R. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.092 · Cited by 115
Self-citationShimizu-Motohashi, Y., Komaki, H., Motohashi, N., Takeda, S., Yokota, T., & Aoki, Y. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9010001 · Cited by 82
Metadata
- Authors
- Malik, V., Rodino‐Klapac, L. R., Viollet, L., Wall, C., King, W., Al‐Dahhak, R., Lewis, S., Shilling, C. J., Kota, J., Serrano‐Munuera, C., Hayes, J., Mahan, J. D., Campbell, K. J., Banwell, B., Dasouki, M., Watts, V., Sivakumar, K., Bien‐Willner, R., Flanigan, K. M., Sahenk, Z., Barohn, R. J., Walker, C. M., & Mendell, J. R.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2010-05-25
- Volume
- 67
- Issue
- 6
- Pages
- 771-780
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2099502558
- Cited by
- 280
- References
- 33
- FWCI
- 10.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.